Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$27.64 USD

27.64
1,867,852

-0.65 (-2.30%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $27.56 -0.08 (-0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Should You Continue to Retain MYGN Stock in Your Portfolio?

by Zacks Equity Research

Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues

by Zacks Equity Research

MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Alcon's (ALC) Market Share Gains, New Launches Aid Growth

by Zacks Equity Research

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.

Should You Hold Hologic (HOLX) Stock in Your Portfolio Now?

by Zacks Equity Research

Hologic's (HOLX) strength in molecular diagnostics and the enriched Breast Health business are encouraging.

Walgreens (WBA) Partners With BARDA to Boost Clinical Research

by Zacks Equity Research

Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.

Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels

by Zacks Equity Research

Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.

Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?

by Zacks Equity Research

Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.

Why You Should Add Exact Sciences (EXAS) to Your Portfolio

by Zacks Equity Research

Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Should Quest Diagnostics (DGX) be in Your Portfolio Now?

by Zacks Equity Research

Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.

Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised

by Zacks Equity Research

Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.

Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 600% and 2.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 4.03% and 92.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

INCY or MYGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

INCY vs. MYGN: Which Stock Is the Better Value Option?

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

by Zacks Equity Research

Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

by Zacks Equity Research

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

by Zacks Equity Research

Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.

Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

by Zacks Equity Research

Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.

Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN (QGEN) Develops Test for Research and CDx Application

by Zacks Equity Research

QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1

by Zacks Equity Research

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.